Workday (WDAY) Holding Maintained by Matrix Capital Management Company Lp; As Astrazeneca Plc (AZN) Stock Price Rose, Shareholder Guardian Capital LP Has Lowered Position

Workday, Inc. (NASDAQ:WDAY) Logo

Matrix Capital Management Company Lp increased its stake in Workday Inc (WDAY) by 27.27% based on its latest 2018Q4 regulatory filing with the SEC. Matrix Capital Management Company Lp bought 300,000 shares as the company’s stock rose 22.90% with the market. The hedge fund held 1.40 million shares of the technology company at the end of 2018Q4, valued at $223.55 million, up from 1.10 million at the end of the previous reported quarter. Matrix Capital Management Company Lp who had been investing in Workday Inc for a number of months, seems to be bullish on the $40.48 billion market cap company. The stock decreased 0.73% or $1.36 during the last trading session, reaching $185.68. About 326,206 shares traded. Workday, Inc. (NYSE:WDAY) has risen 44.59% since March 15, 2018 and is uptrending. It has outperformed by 40.22% the S&P500.

Guardian Capital Lp decreased its stake in Astrazeneca Plc (AZN) by 9.53% based on its latest 2018Q4 regulatory filing with the SEC. Guardian Capital Lp sold 13,481 shares as the company’s stock rose 3.91% with the market. The institutional investor held 127,984 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $4.86 million, down from 141,465 at the end of the previous reported quarter. Guardian Capital Lp who had been investing in Astrazeneca Plc for a number of months, seems to be less bullish one the $104.81 billion market cap company. The stock increased 0.18% or $0.08 during the last trading session, reaching $42.35. About 1.42 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 26.45% since March 15, 2018 and is uptrending. It has outperformed by 22.08% the S&P500. Some Historical AZN News: 17/05/2018 – ASTRAZENECA: SYGMA TRIALS MET PRIMARY EFFICACY OUTCOMES; 12/03/2018 – AstraZeneca: Phase 3 Mystic Trial Delayed for Imfinzi Antibody; 16/05/2018 – PHASE lll IMPOWER150 STUDY SHOWED GENENTECH’S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO…; 11/05/2018 – AstraZeneca’s drug Fasenra flops in COPD trial; 10/05/2018 – GENENTECH- RESULTS FROM IMBLAZE370 SHOWED TREATMENT WITH TECENTRIQ ALONE DID NOT PROVIDE MEANINGFUL CLINICAL BENEFIT COMPARED TO REGORAFENIB; 12/03/2018 – Two PARPi + PD-(L)1 combo data sets in ovarian cancer to be presented as late breaks at #SGO2018 $AZN olaparib + durvalumab in gBRCAm platinum-sensitive relapsed OC $TSRO niraparib + pembrolizumab in platinum-resistant OC; 19/03/2018 – ASTRA REPORTS RESULTS FROM DERIVE PHASE 3 TRIAL ON FARXIGA; 07/05/2018 – Procella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based; 03/04/2018 – Merck, AstraZeneca: EMA Accepts Regulatory Submission for Lynparza in BRCA-Mutated HER2-Negative Metastatic Breast Cancer; 18/05/2018 – ASTRA’S SORIOT: STILL NEED CLARITY ON REGULATION AFTER BREXIT

More notable recent Workday, Inc. (NASDAQ:WDAY) news were published by: Investorplace.com which released: “As the Competition Heats Up, Tableau Stock Is a Little Pricey – Investorplace.com” on March 05, 2019, also Nasdaq.com with their article: “Workday (WDAY) Outpaces Stock Market Gains: What You Should Know – Nasdaq” published on February 11, 2019, Streetinsider.com published: “Workday (WDAY) Said to Have Closed UPS and Caterpillar Deals in Q4 – William Blair – StreetInsider.com” on February 25, 2019. More interesting news about Workday, Inc. (NASDAQ:WDAY) were released by: Nasdaq.com and their article: “Workday (WDAY) Tops Q4 Earnings and Revenue Estimates – Nasdaq” published on March 14, 2019 as well as Investorplace.com‘s news article titled: “9 High-Growth Stocks to Buy Now for Monster Returns – Investorplace.com” with publication date: February 21, 2019.

Since September 17, 2018, it had 0 insider buys, and 29 sales for $173.80 million activity. 4,800 shares were sold by Shaughnessy James P, worth $799,643 on Thursday, January 10. Another trade for 1,434 shares valued at $182,470 was sold by DUFFIELD DAVID A. On Tuesday, January 15 the insider Dermetzis Petros sold $570,465. $663,398 worth of Workday, Inc. (NASDAQ:WDAY) was sold by Bozzini James on Tuesday, January 15. The insider BHUSRI ANEEL sold 6,370 shares worth $1.05M. $1.14M worth of Workday, Inc. (NASDAQ:WDAY) was sold by Fernandez Gomez Luciano on Monday, December 17.

Investors sentiment increased to 1.4 in Q4 2018. Its up 0.28, from 1.12 in 2018Q3. It increased, as 30 investors sold WDAY shares while 113 reduced holdings. 72 funds opened positions while 128 raised stakes. 149.61 million shares or 1.34% more from 147.63 million shares in 2018Q3 were reported. Lazard Asset reported 18,600 shares. 34 are held by Pathstone Family Office Limited Liability Company. Goldman Sachs Group Inc invested in 0.08% or 1.53M shares. Aqr Capital Management Limited Liability Corporation holds 51,253 shares. Sandy Spring Bank holds 200 shares or 0% of its portfolio. Tocqueville Asset Limited Partnership owns 121,465 shares. Asset Mngmt One reported 237,836 shares stake. Piedmont Investment Advsrs reported 10,556 shares. Bp Public Limited Com holds 0.11% or 17,000 shares in its portfolio. Tru Commerce Of Vermont holds 35 shares or 0% of its portfolio. S&Co Inc has 0.33% invested in Workday, Inc. (NASDAQ:WDAY). Ironwood Mngmt Limited Liability invested in 0.47% or 3,215 shares. Millennium Mgmt Lc accumulated 81,476 shares. Captrust Advsrs stated it has 160 shares. Alpha Windward Ltd Liability Corp holds 3,745 shares.

Guardian Capital Lp, which manages about $4.79B US Long portfolio, upped its stake in Canadian Natl Ry Co (NYSE:CNI) by 7,830 shares to 978,844 shares, valued at $72.46M in 2018Q4, according to the filing. It also increased its holding in Cisco Sys Inc (NASDAQ:CSCO) by 14,395 shares in the quarter, for a total of 24,877 shares, and has risen its stake in Methanex Corp (NASDAQ:MEOH).

More notable recent AstraZeneca PLC (NYSE:AZN) news were published by: Seekingalpha.com which released: “European advisory group backs AstraZeneca’s Lynparza in breast cancer – Seeking Alpha” on March 01, 2019, also Benzinga.com with their article: “Earnings Scheduled For February 14, 2019 – Benzinga” published on February 14, 2019, Fool.com published: “Why Marathon Oil, AstraZeneca, and Bloomin’ Brands Jumped Today – Motley Fool” on February 14, 2019. More interesting news about AstraZeneca PLC (NYSE:AZN) were released by: Streetinsider.com and their article: “Merck (MRK), AstraZeneca (AZN) Say LYNPARZA Reduced Risk of Disease Progression or Death as First-Line Maintenance Treatment in gBRCAm – StreetInsider.com” published on February 26, 2019 as well as Fool.com‘s news article titled: “Congress Grills Drugmakers: 5 Key Takeaways – The Motley Fool” with publication date: February 26, 2019.

Workday, Inc. (NASDAQ:WDAY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.